Design and In Silico Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Potential CYP51B Inhibitors Against Aspergillus fumigatus

Shams Khaleel Ibraheem; Basma M. Abd Razik; Hiba Najeh Alsaad; Abdunnaser Abdunnaser Megrahi

doi:10.32947/ajps.v26i3.1420

Authors

Shams Khaleel Ibraheem Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Basma M. Abd Razik Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Hiba Najeh Alsaad Department of Pharmaceutical Chemistry, College of Pharmacy, Basrah University, Basrah, Iraq
Abdunnaser Abdunnaser Megrahi Department of Chemistry, Tripoli University, Libya – Tripoli

DOI:

https://doi.org/10.32947/ajps.v26i3.1420

Keywords:

1,3,4-oxadiazole, Molecular docking, Molecular dynamics simulation, ADME prediction

Abstract

Antifungal resistance and invasive fungal infections remain the major therapeutic issues, especially in patients with impaired immune systems. Aspergillus fumigatus is the main cause of invasive aspergillosis and sterol 14-α-demethylase (CYP51B), a key enzyme in the biosynthetic pathway of ergosterol, is an important target for antifungal therapy. In the present study, four new 1,3,4-oxadiazole derivatives (SH1–SH4) were designed and assessed as possible inhibitors of A. fumigatus CYP51B (PDB ID: 6CR2) by an integrated in silico approach. Binding affinity and interaction patterns within the active site were investigated using the Glide module of the Schrödinger suite. The docking scores of designed compounds ranged from −7.52 to −9.61 kcal/mol. SH4 exhibited the highest docking score (−9.61 kcal/mol), which was very close to Econazole (−9.599 kcal/mol) and better than Clotrimazole and Ketoconazole. SwissADME showed good drug-like property, high gastrointestinal absorption and follow Lipinski’s rule of five. The stability of the SH4–CYP51B complex was also confirmed by 200 ns molecular dynamics simulation in which the protein–ligand interactions remained consistent throughout the simulation. These results indicate that SH4 is a promising oxadiazole-based lead compound for further development of antifungal drugs targeting A. fumigatus CYP51B.

References

1. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):57.

2. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.

3. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20(9):557-571.

4. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22(3):447-465.

5. Latgé JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2020;33(1):e00140-18.

6. Jenks JD, Hoenigl M. Treatment of aspergillosis. J Fungi. 2018;4(3):98.

7. Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.

8. Warrilow AGS, Parker JE, Kelly DE, Kelly SL. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother. 2013;57(3):1352-1360.

9. Lepesheva GI, Waterman MR. Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta. 2007;1770(3):467-477.

10. Meis JF. Azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2017;50(Suppl 1):S20-S20.

11. Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M. Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi. 2016;2(3):21.

12. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383-e392.

13. Hargrove TY, Wawrzak Z, Lamb DC, Guengerich FP, Lepesheva GI. Structure-functional characterization of sterol 14α-demethylase (CYP51). Biochim Biophys Acta. 2015;1850(2):330-339.

14. Warrilow AGS, Melo N, Martel CM, Parker JE, Nes WD, Kelly SL, et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-α demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother. 2010;54(10):4225-4234.

15. Friggeri L, Hargrove TY, Wawrzak Z, Blobaum AL, Rachakonda G, Lindsley CW, et al. Sterol 14α-demethylase structure-based design of VNI derivatives to target fungal infections: synthesis, biological evaluation, and crystallographic analysis. J Med Chem. 2018;61(13):5679-5691.

16. Desai NC, Monapara JD, Jethawa AM, Khedkar VM, Shingate BB. Oxadiazole: A highly versatile scaffold in drug discovery. Arch Pharm (Weinheim). 2022;355(9):e2200123.

17. Wang JJ, Sun W, Jia WD, Bian M, Yu LJ. Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review. J Enzyme Inhib Med Chem. 2022;37(1):2304-2319.

18. El-Masry RM, Kadry HH, Taher AT, Abou-Seri SM. Comparative study of the synthetic approaches and biological activities of the bioisosteres of 1,3,4-oxadiazoles and 1,3,4-thiadiazoles over the past decade. Molecules. 2022;27(9):2709.

19. Jha KK, Samad A, Kumar Y, Shaharyar M, Khosa RL, Jain J, et al. Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives. Eur J Med Chem. 2010;45(11):4963-4967.

20. Bakht MA, Yar MS, Abdel-Hamid SG, Al Qasoumi SI, Samad A. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. Eur J Med Chem. 2010;45(12):5862-5869.

21. Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019;7(2):83-89.

22. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron. 2018;99(6):1129-1143.

23. Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev. 2006;26(5):531-568.

24. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.

25. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, et al., Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J Med Chem. 47 (2004) 1739–1749.

26. K.J. Bowers, D.E. Chow, H. Xu, R.O. Dror, M.P. Eastwood, B.A. Gregersen, et al., Scalable algorithms for molecular dynamics simulations on commodity clusters, Proceedings of the ACM/IEEE SC2006 Conference (2006) 43.

27. F.R. Salsbury, Molecular dynamics simulations of protein dynamics and their relevance to drug discovery, Curr. Opin. Pharmacol. 10 (2010) 738–744.

28. A. Daina, V. Zoete, A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules, ChemMedChem 11 (2016) 1117–1121.